GlassScriptPhysician profile
William E Torres
NPI 1144460684
$86,329.24
in general payments reported to CMS, 2019-2025
66 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,748 · 2020: $4,644 · 2021: $15K · 2022: $11K · 2023: $25K · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $12K · Travel and Lodging: $2,495 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,931.25 |
| Food and Beverage | $12,105.66 |
| Travel and Lodging | $2,495.28 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57,602.20 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Allergan, INC. | $4,384.79 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,995.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,810.49 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,883.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,840.20 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $1,603.03 | 2021 | |
| Pfizer INC. | $1,410.99 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,029.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $768.39 | 2019-2025 | |
| Mylan Specialty L.P. | $609.85 | 2020-2023 | Yupelri |
| Renalytix Ai, INC. | $596.06 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.90 | 2021-2025 | Xifaxan, Ibschek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.26 | 2019-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $461.42 | 2020-2023 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $460.55 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $413.42 | 2019-2024 | |
| Gilead Sciences, INC. | $385.25 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $381.38 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $350.23 | 2019-2021 | |
| Intuity Medical INC | $320.94 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Vanda Pharmaceuticals INC. | $288.76 | 2020-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $286.59 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $218.92 | 2019-2021 | |
| Amgen INC. | $198.67 | 2019-2025 | Krystexxa |
| Aimmune Therapeutics, INC. | $197.42 | 2024-2025 | Zenpep |
| Eisai INC. | $187.53 | 2021 | |
| Exact Sciences Corporation | $186.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.87 | 2023-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $164.48 | 2022-2024 | Gvoke Hypopen |
| Stryker Corporation | $163.29 | 2023 | Inspace |
| Merck Sharp & Dohme LLC | $157.97 | 2019-2025 | Pifeltro, Capvaxive |
| Abbott Laboratories | $151.90 | 2021-2024 | Freestyle Libre 3 |
| Painteq LLC | $140.22 | 2022 | |
| Cipher Pharmaceuticals US LLC | $138.11 | 2025 | Spinosad, Natroba |
| Takeda Pharmaceuticals U.S.A., INC. | $122.29 | 2021 | |
| Alkermes, INC. | $122.23 | 2025 | Aristada, Lybalvi |
| Astellas Pharma US INC | $104.46 | 2020-2023 | Veozah |
| Scpharmaceuticals INC. | $90.22 | 2025 | |
| Intra-Sana Laboratories | $70.15 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Amneal Pharmaceuticals LLC | $68.98 | 2023 | Lyvispah |
| Axsome Therapeutics, INC. | $65.53 | 2025 | Symbravo, Auvelity |
| Kowa Pharmaceuticals America, INC. | $56.85 | 2020-2025 | Zoryve, Seglentis, Livalo |
| Corcept Therapeutics | $48.63 | 2019-2025 | Korlym |
| Bausch Health US, LLC | $46.23 | 2019 | |
| Shield Therapeutics INC | $43.45 | 2023-2024 | Accrufer |
| Ardelyx, INC. | $40.84 | 2024-2025 | Ibsrela |
| Scynexis, INC. | $39.90 | 2022 | |
| Smith+Nephew, INC. | $28.66 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $28.32 | 2024 | |
| Forte Bio-Pharma LLC | $26.77 | 2024 | Prolate, Nalocet |
| Radius Health, INC. | $26.36 | 2019 | |
| Hologic Sales and Service, LLC | $23.68 | 2022 | |
| Advanced Respiratory, INC | $21.98 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.24 | 2023 | Quviviq |
| Lifescan, INC. | $20.82 | 2023 | |
| Arbor Pharmaceuticals, INC. | $20.47 | 2019 | |
| Lundbeck LLC | $19.70 | 2025 | Rexulti |
| Corium, LLC | $17.18 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Hikma Pharmaceuticals USA | $16.05 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.05 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.62 | 2020 | |
| Circassia INC. | $15.19 | 2020 | |
| Lupin INC. | $13.12 | 2020 | |
| Almatica Pharma LLC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William E Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.